Search Results - "LE, Robert Q"

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies by REZVANI, Katayoun, YONG, Agnes S. M, BARRETT, A. John, MIELKE, Stephan, JAFARPOUR, Behnam, SAVANI, Bipin N, LE, Robert Q, ENIAFE, Rhoda, MUSSE, Laura, BOSS, Carol, KURLANDER, Roger

“…We previously showed that vaccination with one dose of PR1 and WT1 peptides induces transient anti-leukemia immunity. We hypothesized that maintenance of a…”
Get full text

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome by Le, Robert Q., Li, Liang, Yuan, Weishi, Shord, Stacy S., Nie, Lei, Habtemariam, Bahru A., Przepiorka, Donna, Farrell, Ann T., Pazdur, Richard

“…On August 30, 2017, the U.S. Food and Drug Administration approved Actemra (tocilizumab, Genentech, Inc., South San Francisco, CA) for the treatment of severe…”
Get full text

Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors by Jain, Natasha A., Chen, Marcus Y., Shanbhag, Sujata, Anandi, Prathima, Tian, Xin, Ito, Sawa, Pophali, Priyanka A., Doucette, Kimberly, Le, Robert Q., Chawla, Upneet, Koklanaris, Eleftheria, Childs, Richard W., Barrett, A. John, Battiwalla, Minoo

“…Long-term allogeneic hematopoietic cell transplant (allo-HCT) survivors suffer an elevated risk of coronary heart disease (CHD). We conducted a prospective,…”
Get full text

Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia by Le, Robert Q., Przepiorka, Donna, Chen, Haiyan, Shen, Yuan Li, Pulte, E. Dianne, Norsworthy, Kelly, Theoret, Marc R., De Claro, R. Angelo

“…•CRh correlated with TI and delayed time to severe bleeding or infection with nonmyelosuppressive targeted therapies.•CRh may denote palliative benefits for…”
Get full text

FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy by Le, Robert Q, Wang, Xin, Zhang, Hongfei, Li, Hongshan, Przepiorka, Donna, Vallejo, Jonathon, Leong, Ruby, Ma, Lian, Goldberg, Kirsten B, Pazdur, Richard, Theoret, Marc R, De Claro, Angelo

“…On September 22, 2021, the Food and Drug Administration approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) after the failure…”
Get full text

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy by Przepiorka, Donna, Le, Robert Q, Ionan, Alexei, Li, Ruo-Jing, Wang, Ying-Hong, Gudi, Ramadevi, Mitra, Soumya, Vallejo, Jonathon, Okusanya, Olanrewaju O, Ma, Lian, Yang, Yuching, Patel, Paresma, Mezaache, Djelila, Shah, Rakhi, Banerjee, Anamitro, McLamore, Sherita, Maung, Adam N, Goldberg, Kirsten B, Pazdur, Richard, Theoret, Marc R, De Claro, R Angelo

“…On July 16, 2021, the FDA approved belumosudil, a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic GvHD (cGvHD) after failure…”
Get full text

Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia by Pollyea, Daniel A, Barrett, John, DiNardo, Courtney D, Michaelis, Laura C, Roboz, Gail J, Le, Robert Q, Norsworthy, Kelly J, de Claro, R Angelo, Theoret, Marc R, Pazdur, Richard

“…The Food and Drug Administration Oncology Center of Excellence initiated Project 2025 to develop 5-year goals in specific areas of oncology drug development…”
Get full text

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: the Immune Dysregulation and Pathobiology Working Group Report by Gea-Banacloche, Juan, MD, Komanduri, Krishna, MD, Carpenter, Paul, MD, Paczesny, Sophie, MD, PhD, Sarantopoulos, Stefanie, MD, PhD, Young, Jo-Anne, MD, El Kassar, Nahed, MD, PhD, Le, Robert Q., MD, PhD, Schultz, Kirk, MD, Griffith, Linda M., MD, Savani, Bipin, MD, Wingard, John R

“…Abstract Immune reconstitution following hematopoietic stem cell transplantation (HCT) beyond one year is not completely understood. Many transplant recipients…”
Get full text

Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events by Pophali, Priyanka A, Klotz, Jeffrey K, Ito, Sawa, Jain, Natasha A, Koklanaris, Eleftheria, Le, Robert Q, Hourigan, Christopher S, Savani, Bipin N, Chawla, Kamna, Shanbhag, Sujata, Barrett, A. John, Battiwalla, Minoo

“…Long-term survivors of allogeneic stem cell transplantation (SCT) have increased risk of cardiovascular disease. We retrospectively studied cardiovascular risk…”
Get full text

CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation by Anand, Ankit, Anandi, Prathima, Jain, Natasha A., Lu, Kit, Dunavin, Neil, Hourigan, Christopher S., Le, Robert Q., Chokshi, Puja D., Ito, Sawa, Stroncek, David F., Sabatino, Marianna, Barrett, A. John, Battiwalla, Minoo

“…Objective The purpose of the present study was to evaluate the impact of ex vivo T cell depleted (TCD) by CD34+ selection on the incidence and severity of…”
Get full text

Minor ABO Incompatibility Does Not Impact Nonrelapse Mortality in T Cell–Depleted Human Leukocyte Antigen–Matched Sibling Transplantation by Chokshi, Puja, Anandi, Prathima, Jain, Natasha, Dunavin, Neil, Le, Robert Q, Ito, Sawa, Barrett, John, Battiwalla, Minoo

Get full text

Blood Stream Infection Is Frequent during Conditioning but Does Not Impact Allogeneic Transplant Outcomes in the Modern Era by Anandi, Prathima, MD, Dunavin, Neil, MD, Jain, Natasha A., MD, Chokshi, Puja D., MD, Anand, Ankit, MD, Le, Robert Q., MD, Phd, Ito, Sawa, MD, Barrett, A. John, MD, Battiwalla, Minoo, MD, MS

Get full text

Minor ABO Incompatibility Does Not Impact Non-Relapse Mortality in T-Cell Depleted HLA-Matched Sibling Transplantation by Chokshi, Puja D., MD, Anandi, Prathima, MD, Jain, Natasha A., MD, Dunavin, Neil, MD, Le, Robert Q., MD, Phd, Ito, Sawa, MD, Barrett, A. John, MD, Battiwalla, Minoo, MD, MS

Get full text

Bone Mineral Density (BMD) Improves in Survivors in Their Second Decade Post-Allogeneic Stem Cell Transplantation and Is Influenced By Body Mass Index (BMI) and Age by Anandi, Prathima, MD, Jain, Natasha A., MD, Wu, Colin, Phd, Tian, Xin, PhD, Pophali, Priyanka A., MD, Koklanaris, Eleftheria, RN, Dunavin, Neil, MD, Ito, Sawa, MD, Le, Robert Q., MD, Phd, Savani, Bipin N., MD, Barrett, A. John, MD, Battiwalla, Minoo, MD, MS

Get full text

Reduced Non Relapse Mortality (NRM) and Survivable Acute Graft Versus Host Disease (GVHD) in the Current Era of Myeloablative Ex Vivo T-Cell Depleted (TCD) Transplantation by Jain, Natasha A, Anandi, Prathima, Chawla, Upneet, Ito, Sawa, Draper, Debbie, Koklanaris, Eleftheria, Hauffe, Sara, Superata, Jeanine, Le, Robert Q., Stroncek, David, Muranski, Pawel, Battiwalla, Minoo, Barrett, John

“…Introduction: Little is known about the lethality of acute GVHD (aGVHD) in T -cell depleted (TCD) allogeneic hematopoietic stem cell transplantation (HSCT). We…”
Get full text

Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation by Le, Robert Q., Tian, Xin, Jain, Natasha A, Lu, Kit, Ito, Sawa, Draper, Debbie A, Anandi, Prathima, Hourigan, Christopher S., Dunavin, Neil, Barrett, John, Battiwalla, Minoo

“…Ex vivo T cell depletion (TCD) of the graft by CD34+ selection improves the tolerability of allogeneic hematopoietic stem cell transplantation (HCT). Clinical…”
Get full text

Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct by Le, Robert Q., Anandi, Prathima, Tian, Xin, Ito, Sawa, Jain, Natasha A, Goswami, Meghali, Lai, Catherine E., Hourigan, Christopher S., Adams, Sharon, Hensel, Nancy F., Barrett, Austin John, Battiwalla, Minoo

“…INTRODUCTION: Relapse is the most important cause of post-transplant mortality. The interaction between killer immunoglobulin-like receptors (KIRs) of donor…”
Get full text

CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation by Anand, Ankit, Anandi, Prathima, Natasha, Jain A., Lu, Kit, Dunavin, Neil, Hourigan, Christopher S., Le, Robert Q., Chokshi, Puja D., Ito, Sawa, Stroncek, David F., Sabatino, Marianna, Barrett, John, Battiwalla, Minoo

“…▪ Oral Mucositis (OM) is a frequent and debilitating complication of standard myeloablative T-replete allogeneic stem cell transplantation (allo-SCT), often…”
Get full text

Chronic Graft Versus Host Disease (GVHD) Does Not Impact Cardiovascular Risk Factors in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) up to the Second Decade Post-Transplant by Pophali, Priyanka A, Chawla, Kamna, Koklanaris, Eleftheria K., Antia, Avan, Chawla, Simar, Ito, Sawa, Klotz, Jeffrey K., Le, Robert Q., Barrett, A. John, Battiwalla, Minoo

“…Abstract 4099 Long term survivors of allogeneic SCT have increased risk factors for cardiovascular disease. The reason for this is unclear but chronic GVHD…”
Get full text

Clinical and Biological Predictors of Outcome Following Relapse of Chronic Myeloid Leukemia after Allogeneic Stem Cell Transplantation by Jain, Natasha A., Ito, Sawa, Tian, Xin, Kurlander, Roger, Battiwalla, Minoo, Lu, Kit, Savani, Bipin N., Malkovska, Vera, Rezvani, Katayoun, Le, Robert Q, Shenoy, Aarthi, Hourigan, Christopher S., Keyvanfar, Keyvan, Koklanaris, Eleftheria, Superata, Jeanine, Muranski, Pawel, Barrett, A. John, Yong, Agnes S.M.

“…While there are now fewer allogeneic stem cell transplants (allo-SCT) performed for chronic myeloid leukemia (CML), leukemic relapse post-transplant remains a…”
Get full text